12 USD
-0.21 (-1.72%)
At close: Feb 3, 2026
12 USD
0 (0%)
After Hours: 2/3/2026, 4:10:08 PM
We assign a fundamental rating of 4 out of 10 to XRAY. XRAY was compared to 186 industry peers in the Health Care Equipment & Supplies industry. While XRAY is still in line with the averages on profitability rating, there are concerns on its financial health. XRAY has a bad growth rate and is valued cheaply. Finally XRAY also has an excellent dividend rating.
1. Profitability
1.1 Basic Checks
- XRAY had positive earnings in the past year.
- In the past year XRAY had a positive cash flow from operations.
- In the past 5 years XRAY reported 4 times negative net income.
- In the past 5 years XRAY always reported a positive cash flow from operatings.
1.2 Ratios
- XRAY has a Return On Assets (-15.60%) which is in line with its industry peers.
- XRAY's Return On Equity of -59.68% is in line compared to the rest of the industry. XRAY outperforms 47.31% of its industry peers.
- XRAY's Return On Invested Capital of 5.04% is fine compared to the rest of the industry. XRAY outperforms 76.88% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for XRAY is below the industry average of 8.80%.
- The 3 year average ROIC (4.11%) for XRAY is below the current ROIC(5.04%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -15.6% | ||
| ROE | -59.68% | ||
| ROIC | 5.04% |
ROA(3y)-10.01%
ROA(5y)-5.27%
ROE(3y)-25.27%
ROE(5y)-13.81%
ROIC(3y)4.11%
ROIC(5y)4.26%
1.3 Margins
- XRAY has a better Operating Margin (7.48%) than 74.73% of its industry peers.
- XRAY's Operating Margin has declined in the last couple of years.
- Looking at the Gross Margin, with a value of 51.10%, XRAY is in line with its industry, outperforming 46.77% of the companies in the same industry.
- In the last couple of years the Gross Margin of XRAY has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.48% | ||
| PM (TTM) | N/A | ||
| GM | 51.1% |
OM growth 3Y-25.8%
OM growth 5Y-12.74%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.16%
GM growth 5Y-0.95%
2. Health
2.1 Basic Checks
- XRAY has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
- The number of shares outstanding for XRAY has been reduced compared to 1 year ago.
- Compared to 5 years ago, XRAY has less shares outstanding
- XRAY has a worse debt/assets ratio than last year.
2.2 Solvency
- XRAY has an Altman-Z score of 0.95. This is a bad value and indicates that XRAY is not financially healthy and even has some risk of bankruptcy.
- XRAY has a Altman-Z score of 0.95. This is comparable to the rest of the industry: XRAY outperforms 50.54% of its industry peers.
- XRAY has a debt to FCF ratio of 29.94. This is a negative value and a sign of low solvency as XRAY would need 29.94 years to pay back of all of its debts.
- XRAY has a better Debt to FCF ratio (29.94) than 68.28% of its industry peers.
- A Debt/Equity ratio of 1.36 is on the high side and indicates that XRAY has dependencies on debt financing.
- XRAY has a Debt to Equity ratio of 1.36. This is in the lower half of the industry: XRAY underperforms 77.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.36 | ||
| Debt/FCF | 29.94 | ||
| Altman-Z | 0.95 |
ROIC/WACC0.55
WACC9.18%
2.3 Liquidity
- A Current Ratio of 1.47 indicates that XRAY should not have too much problems paying its short term obligations.
- The Current ratio of XRAY (1.47) is worse than 74.19% of its industry peers.
- A Quick Ratio of 0.99 indicates that XRAY may have some problems paying its short term obligations.
- The Quick ratio of XRAY (0.99) is worse than 74.19% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.47 | ||
| Quick Ratio | 0.99 |
3. Growth
3.1 Past
- XRAY shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -14.59%.
- XRAY shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -7.38% yearly.
- Looking at the last year, XRAY shows a decrease in Revenue. The Revenue has decreased by -7.08% in the last year.
- XRAY shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -1.17% yearly.
EPS 1Y (TTM)-14.59%
EPS 3Y-16.51%
EPS 5Y-7.38%
EPS Q2Q%-26%
Revenue 1Y (TTM)-7.08%
Revenue growth 3Y-3.58%
Revenue growth 5Y-1.17%
Sales Q2Q%-4.94%
3.2 Future
- The Earnings Per Share is expected to grow by 7.40% on average over the next years.
- XRAY is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.34% yearly.
EPS Next Y-1.98%
EPS Next 2Y-2.65%
EPS Next 3Y2.27%
EPS Next 5Y7.4%
Revenue Next Year-4.27%
Revenue Next 2Y-1.79%
Revenue Next 3Y-0.41%
Revenue Next 5Y1.34%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 7.59, which indicates a rather cheap valuation of XRAY.
- Compared to the rest of the industry, the Price/Earnings ratio of XRAY indicates a rather cheap valuation: XRAY is cheaper than 97.31% of the companies listed in the same industry.
- The average S&P500 Price/Earnings ratio is at 28.41. XRAY is valued rather cheaply when compared to this.
- Based on the Price/Forward Earnings ratio of 7.58, the valuation of XRAY can be described as very cheap.
- 97.31% of the companies in the same industry are more expensive than XRAY, based on the Price/Forward Earnings ratio.
- The average S&P500 Price/Forward Earnings ratio is at 25.64. XRAY is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.59 | ||
| Fwd PE | 7.58 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of XRAY indicates a rather cheap valuation: XRAY is cheaper than 96.77% of the companies listed in the same industry.
- 79.57% of the companies in the same industry are more expensive than XRAY, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 29.93 | ||
| EV/EBITDA | 7.23 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.65%
EPS Next 3Y2.27%
5. Dividend
5.1 Amount
- XRAY has a Yearly Dividend Yield of 5.17%, which is a nice return.
- Compared to an average industry Dividend Yield of 0.21, XRAY pays a better dividend. On top of this XRAY pays more dividend than 99.46% of the companies listed in the same industry.
- Compared to an average S&P500 Dividend Yield of 1.83, XRAY pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 5.17% |
5.2 History
- On average, the dividend of XRAY grows each year by 11.21%, which is quite nice.
- XRAY has been paying a dividend for at least 10 years, so it has a reliable track record.
- XRAY has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.
Dividend Growth(5Y)11.21%
Div Incr Years6
Div Non Decr Years30
5.3 Sustainability
- The earnings of XRAY are negative and hence is the payout ratio. XRAY will probably not be able to sustain this dividend level.
- The dividend of XRAY is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DP-14.4%
EPS Next 2Y-2.65%
EPS Next 3Y2.27%
12
-0.21 (-1.72%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-06 2025-11-06/bmo
Earnings (Next)02-26 2026-02-26/amc
Inst Owners107.4%
Inst Owner Change-1.15%
Ins Owners0.24%
Ins Owner Change-2.09%
Market Cap2.39B
Revenue(TTM)3.62B
Net Income(TTM)-882.00M
Analysts68.18
Price Target12.86 (7.17%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 5.17% |
Yearly Dividend0.62
Dividend Growth(5Y)11.21%
DP-14.4%
Div Incr Years6
Div Non Decr Years30
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-8.77%
Min EPS beat(2)-19.03%
Max EPS beat(2)1.49%
EPS beat(4)2
Avg EPS beat(4)-3.17%
Min EPS beat(4)-40.52%
Max EPS beat(4)45.37%
EPS beat(8)3
Avg EPS beat(8)-1.68%
EPS beat(12)6
Avg EPS beat(12)4.59%
EPS beat(16)7
Avg EPS beat(16)1.99%
Revenue beat(2)0
Avg Revenue beat(2)-1.42%
Min Revenue beat(2)-1.67%
Max Revenue beat(2)-1.16%
Revenue beat(4)1
Avg Revenue beat(4)-1.42%
Min Revenue beat(4)-3.62%
Max Revenue beat(4)0.77%
Revenue beat(8)2
Avg Revenue beat(8)-1.44%
Revenue beat(12)5
Avg Revenue beat(12)-0.9%
Revenue beat(16)5
Avg Revenue beat(16)-2.02%
PT rev (1m)0.57%
PT rev (3m)-20.59%
EPS NQ rev (1m)0.15%
EPS NQ rev (3m)-41.55%
EPS NY rev (1m)0.09%
EPS NY rev (3m)-14.72%
Revenue NQ rev (1m)0.1%
Revenue NQ rev (3m)-1.46%
Revenue NY rev (1m)0.05%
Revenue NY rev (3m)-0.21%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.59 | ||
| Fwd PE | 7.58 | ||
| P/S | 0.66 | ||
| P/FCF | 29.93 | ||
| P/OCF | 10.84 | ||
| P/B | 1.62 | ||
| P/tB | N/A | ||
| EV/EBITDA | 7.23 |
EPS(TTM)1.58
EY13.17%
EPS(NY)1.58
Fwd EY13.19%
FCF(TTM)0.4
FCFY3.34%
OCF(TTM)1.11
OCFY9.23%
SpS18.16
BVpS7.41
TBVpS-4.29
PEG (NY)N/A
PEG (5Y)N/A
Graham Number16.23
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -15.6% | ||
| ROE | -59.68% | ||
| ROCE | 6.38% | ||
| ROIC | 5.04% | ||
| ROICexc | 5.51% | ||
| ROICexgc | 13.81% | ||
| OM | 7.48% | ||
| PM (TTM) | N/A | ||
| GM | 51.1% | ||
| FCFM | 2.21% |
ROA(3y)-10.01%
ROA(5y)-5.27%
ROE(3y)-25.27%
ROE(5y)-13.81%
ROIC(3y)4.11%
ROIC(5y)4.26%
ROICexc(3y)4.36%
ROICexc(5y)4.5%
ROICexgc(3y)15.64%
ROICexgc(5y)20.94%
ROCE(3y)5.38%
ROCE(5y)5.49%
ROICexgc growth 3Y-31.16%
ROICexgc growth 5Y-12.42%
ROICexc growth 3Y-13.44%
ROICexc growth 5Y-4.44%
OM growth 3Y-25.8%
OM growth 5Y-12.74%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.16%
GM growth 5Y-0.95%
F-Score4
Asset Turnover0.64
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.36 | ||
| Debt/FCF | 29.94 | ||
| Debt/EBITDA | 3.26 | ||
| Cap/Depr | 40.63% | ||
| Cap/Sales | 3.89% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 35.76% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.47 | ||
| Quick Ratio | 0.99 | ||
| Altman-Z | 0.95 |
F-Score4
WACC9.18%
ROIC/WACC0.55
Cap/Depr(3y)46.81%
Cap/Depr(5y)41.51%
Cap/Sales(3y)4.1%
Cap/Sales(5y)3.65%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-14.59%
EPS 3Y-16.51%
EPS 5Y-7.38%
EPS Q2Q%-26%
EPS Next Y-1.98%
EPS Next 2Y-2.65%
EPS Next 3Y2.27%
EPS Next 5Y7.4%
Revenue 1Y (TTM)-7.08%
Revenue growth 3Y-3.58%
Revenue growth 5Y-1.17%
Sales Q2Q%-4.94%
Revenue Next Year-4.27%
Revenue Next 2Y-1.79%
Revenue Next 3Y-0.41%
Revenue Next 5Y1.34%
EBIT growth 1Y3.04%
EBIT growth 3Y-28.45%
EBIT growth 5Y-13.75%
EBIT Next Year42.48%
EBIT Next 3Y13.79%
EBIT Next 5Y11.96%
FCF growth 1Y-63.3%
FCF growth 3Y-18.29%
FCF growth 5Y-11.45%
OCF growth 1Y-38.44%
OCF growth 3Y-11.14%
OCF growth 5Y-6.32%
DENTSPLY SIRONA INC / XRAY FAQ
What is the ChartMill fundamental rating of DENTSPLY SIRONA INC (XRAY) stock?
ChartMill assigns a fundamental rating of 4 / 10 to XRAY.
What is the valuation status for XRAY stock?
ChartMill assigns a valuation rating of 7 / 10 to DENTSPLY SIRONA INC (XRAY). This can be considered as Undervalued.
How profitable is DENTSPLY SIRONA INC (XRAY) stock?
DENTSPLY SIRONA INC (XRAY) has a profitability rating of 4 / 10.
Can you provide the PE and PB ratios for XRAY stock?
The Price/Earnings (PE) ratio for DENTSPLY SIRONA INC (XRAY) is 7.59 and the Price/Book (PB) ratio is 1.62.
Can you provide the dividend sustainability for XRAY stock?
The dividend rating of DENTSPLY SIRONA INC (XRAY) is 7 / 10 and the dividend payout ratio is -14.4%.